BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Sponsor: Novartis Pharmaceuticals
A PHASE1/PHASE2 clinical study on Cancer, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 21 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
21 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Phase: PHASE2 → PHASE1_PHASE2
-
May 2021 — Nov 2021 [monthly]
Completed PHASE2
▶ Show 16 earlier versions
-
Jan 2021 — May 2021 [monthly]
Completed PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2020 — Oct 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aichi, Japan , Amsterdam, Netherlands , Barcelona, Spain , Birmingham, United Kingdom , Boston, United States , Brussels, Belgium , Candiolo, Italy , Chapel Hill, United States , Chiba, Japan , Leuven, Belgium and 9 more locations